A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
Price : $35 *
At a glance
- Drugs Dalbavancin (Primary)
- Indications Osteomyelitis
- Focus Therapeutic Use
- Sponsors Allergan
- 18 Sep 2017 Status changed from recruiting to discontinued.
- 05 May 2017 Status changed from not yet recruiting to recruiting.
- 29 Mar 2017 New trial record